Baxter International reported $11.5B of revenue over the trailing twelve months, +5.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $11.5B (to Q2 2026). Net income: −$1.06B, trailing twelve months to Q2 2026. Operating margin: −2.2%, trailing twelve months to Q2 2026. EPS: −$2.08, trailing twelve months to Q2 2026.

BAXBaxter International

Healthcare

$24.36+3.0% 1Y

$24.36

$15.7952 weeks$28.35

BAX as reported

Baxter International reported $11.5B of revenue over the trailing twelve months, +5.4% on the year before. 11 reported series are charted on this page, each one as filed.

$11.5B

Revenue, trailing twelve months · to Q2 2026 · +5.4% against the twelve months before

Net income: −$1.06B
Net income · +586% year on year · trailing twelve months to Q2 2026
Operating margin: −2.2%
Operating margin · trailing twelve months to Q2 2026
EPS: −$2.08
EPS · +593% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BAX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$11.5B	+5.4%	Q2 2026
Net income	−$1.06B	+586%	Q2 2026
EPS	−$2.08	+593%	Q2 2026
Gross margin	30%	n/a	Q2 2026
Operating margin	−2.2%	n/a	Q2 2026
Net margin	−9.0%	n/a	Q2 2026
ROE	−14%	n/a	Q2 2026
ROA	−4.3%	n/a	Q2 2026
ROIC	−2.8%	n/a	Q2 2026
Free cash flow	$1.15B	n/a	Q4 2023 · 10 quarters behind
P/E	49.5	n/a	Q3 2024 · 7 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.